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ABSTRACT Cryptococcus neoformans is an important fungal pathogen of immunocompromised individuals, with a close relative,
Cryptococcus gattii, emerging as a serious threat for the immunocompetent. During initial infection, C. neoformans colonizes
theairspacesofthelungs,resultinginpneumonia,andsubsequentlymigratestothecentralnervoussystem(CNS).Wesoughtto
understandfungalcarbonutilizationduringcolonizationofthesefundamentallydifferentnicheswithinthehost,inparticular
therolesofgluconeogenesisandglycolysis.Wecreatedmutantsatkeypointsinthegluconeogenesis/glycolysismetabolicpath-
waysthatarerestrictedforgrowthonlactateandglucose,respectively.Aphosphoenolpyruvatecarboxykinasemutant(the
pck1mutant),blockedforentryof2-and3-carbonsubstratesintogluconeogenesisandattenuatedforvirulenceinamurine
inhalationmodel,showedwild-type(WT)persistenceinarabbitcerebrospinalﬂuid(CSF)modelofcryptococcosis.Conversely,
boththepyruvatekinase(pyk1)andthehexosekinaseIandII(hxk1/hxk2)mutants,whichshowimpairedglucoseutiliza-
tion,exhibitedseverelyattenuatedvirulenceinthemurineinhalationmodelofcryptococcosisanddecreasedpersistenceinthe
CNSinboththerabbitCSFandthemurineinhalationmodelswhiledisplayingadequatepersistenceinthelungsofmice.These
datasuggestthatglucoseutilizationiscriticalforvirulenceofC. neoformansandpersistenceoftheyeastintheCNS.
IMPORTANCE Cryptococcus neoformans is an emerging fungal pathogen of humans and is responsible for approximately 625,000
deathsannuallyamongthosesufferingfromHIVinfection/AIDS.Theabilityofthisfungustopersistinthehost,coupledwith
itspropensitytocolonizetheCNS,makestheunderstandingofnutrientacquisitioninthehostaprimaryconcern.Inthisstudy,
we report a requirement of glucose utilization for virulence of C. neoformans that is separate from its role in ATP production in
thepathogen.Furthermore,weshowthatinhibitionofglycolysisisaviableantifungaldrugtarget,andimpairedATPproduc-
tionviathePYK1deletionmayserveasamodelfordormant/chronicfungalinfectioninthehost.Takentogether,theseresults
demonstratethecriticalimportanceofunderstandingbasicmetabolicprocessesofthefungusinthecontextofhost-pathogen
interactions.
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C
ryptococcus neoformans is a major human and animal patho-
gen responsible for cryptococcal meningoencephalitis in im-
munocompromised individuals. Found worldwide, C. neofor-
mans is commonly isolated from environmental samples (1).
Cryptococcosis is currently the third highest cause of mortality
duetoinfectiousdiseasesinsub-SaharanAfrica(2),andanongo-
ing outbreak of Cryptococcus gattii infections is causing measur-
able human and animal morbidity and mortality in the Paciﬁc
Northwest (3–5). Unlike many other opportunistic fungal patho-
gens(e.g.,Aspergillusfumigatus),C.neoformansappearstobespe-
ciallyadaptedforsurvivalinthehumanhostandpossessesanum-
ber of pathogenicity factors involved in this interaction (6).
However, this pathogen does not appear to be part of the normal
human ﬂora, despite its intimate association with monocytes and
the central nervous system (CNS) during disease (7–12).
Several virulence-associated traits have clearly been identiﬁed
as required for cryptococcal pathogenesis, including growth at
37°C, production of capsule, melanin biosynthesis, secretion of
phospholipase,andproductionofmannitol(13,14).Thepolysac-
charide capsule has received much attention due to its immuno-
modulatory properties (12) and is mainly composed of GXM
(1,3-linked mannose subunits with various xylosyl and
-glucuronyl substitutions), which varies by serotype. Interest-
ingly, elimination of individual sugar components (e.g., xylose)
results in virulence defects (15). Therefore, understanding the
process of carbon assimilation by C. neoformans and therefore
subsequent capsule biosynthesis is crucial for a proper under-
standing of virulence.
Recently, Barelle and colleagues demonstrated that the asco-
mycete yeast pathogen Candida albicans alters its carbon assimi-
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cycle) to fermentative (i.e., glycolysis) metabolism during the on-
set of systemic infection in mice (16). In their study, they built
upon previous studies showing the seemingly paradoxical impor-
tance of both fermentative and nonfermentative carbon metabo-
lism in C. albicans virulence (17–19). Using mutants blocked in
various core carbon metabolic pathways, Barelle and colleagues
showed that the glyoxylate cycle and gluconeogenesis pathways
were essential for optimal survival of C. albicans during its initial
interactions with immune cells (16). Later, as the yeast cells colo-
nizethebloodstreamandinternalorgansofthemammalianhost,
glycolysis emerges as the main carbon assimilation pathway. This
study emphasized the changes in carbon assimilation a pathogen
must make to persist in spite of changing host defenses.
Presumably,C.neoformansalsoencountersseveralfundamen-
tallydifferentmicroenvironmentsinthehostduringthecourseof
disease progression. For instance, we recently demonstrated that
persistence of C. neoformans in the cerebrospinal ﬂuid (CSF) mi-
croenvironment was inﬂuenced by a number of different cellular
pathways, including maintenance of ionic balance and inositol
metabolism (20). Previous studies touching on carbon metabo-
lism and C. neoformans pathogenesis show mixed results regard-
ingtheroleofnonpreferredcarbonsourcesindiseaseprogression
(21–24). However, nonpreferred carbon sources such as lactate
and acetate are likely important early in establishment of a pul-
monary infection. For example, the acetyl-coenzyme A (CoA)
synthase gene ACS1 has been demonstrated as necessary for full
virulence in C. neoformans (21). In this same study, Hu and col-
leagues showed that Snf1, shown to be a major regulator of non-
preferred carbon utilization via the phosphorylation of the global
carbon catabolite repressor Mig1 in Saccharomyces cerevisiae,i s
also required for full virulence in a murine inhalation model of
cryptococcosis.However,therearedifferencesbetweenC.neofor-
mans and other pathogenic fungi in the relationship of carbon
utilization and virulence. For example, the glyoxylate shunt is not
required for virulence in this basidiomycete pathogen as it is for
the full virulence of the ascomycete C. albicans (18, 22, 24).
Theabilityofapathogentocausediseaseisinextricablylinked
to its ability to procure nutrients from its host, and carbon in
particular.Therefore,asolidunderstandingofcarbonacquisition
by a microbial invader or tumor cell is essential for identifying
potential targets for the development of drug therapies. This line
of reasoning is currently being employed with regard to cancer
treatment. Cancer cells are known to exhibit differential carbon
metabolism compared to normal host tissue (25). For instance,
malignantcellsswitchonproliferativecarbonmetabolismdepen-
dent on glycolysis for the production of their biomass, making
themvulnerabletoinhibitorsofglycolysis(26).Theapparentsim-
ilarities observed between malignancies and eukaryotic microor-
ganisms regarding carbon metabolism during host invasion (25)
warrantsfurtherinvestigationofcarbonmetabolismduringinfec-
tionforuniqueweaknessesthatcanbetargetedintreatmentstrat-
egies for pathogenic fungi such as C. neoformans.
Therefore,wesoughttounderstandtherelationshipofglucose
anabolic and catabolic processes to pathogenicity in C. neofor-
mans.Toinvestigatetherolesofglycolysisandgluconeogenesisin
host colonization by Cryptococcus, we procured carbon metabo-
lism mutants previously described as well as constructed addi-
tional mutants to block key steps in glycolysis/gluconeogenesis
and carbon catabolite repression (CCR) (see Table S1 and Fig. S1
inthesupplementalmaterial)(21,22).Byexaminingtheeffectsof
these mutations on virulence at several body sites using both the
murine inhalation (pulmonary infection and dissemination) and
the rabbit CSF (direct inoculation of the subarachnoid space)
models of cryptococcosis, we demonstrate that gluconeogenic
carbon assimilation is sufﬁcient for the initial establishment of
infection but that glycolysis is critical for persistence of C. neofor-
mans in the CNS and virulence in the host.
RESULTS
Role of gluconeogenesis in C. neoformans persistence in the
CNS. Since prior reports have demonstrated the importance of
gluconeogenesis during lung infection by C. neoformans,w e
sought to establish a possible role for gluconeogenesis in survival
of C. neoformans in the CNS. We used real-time PCR to measure
expression of the phosphoenolpyruvate carboxykinase gene
PCK1,whichencodesthemaingatewayenzymeforentryof2-and
3-carbon substrates into gluconeogenesis, under different growth
conditions. Weconﬁrmed elevated PCK1 expression in low glucose
concentrations, as expected from results obtained using S. cerevisiae
(27), and also observed increased expression due to exposure to ex
vivopooledhumanCSF(Fig.1A).ThisincreasedPCK1expressionin
strainH99wasalsoobservedinvivointherabbitCSFmodelofcryp-
tococcosis and in cryptococcal strains taken directly from human
patient CSF samples compared to the expression of PCK1 in these
samplesgrowninvitroat37°C(Fig.1BandC).However,despitethis
elevated expression of PCK1, independent pck1 deletion mutants
showed no defects in CNS persistence or viability in the rabbit CSF
model (data not shown).
We also tested other previously published mutants related to
nonpreferred carbon assimilation in the rabbit CSF model. A
snf1deletionmutant,whichisthoughttorepresentamajorreg-
ulator of nonpreferred carbon utilization based on ﬁndings in
S. cerevisiae, demonstrated moderately reduced persistence in the
rabbit CSF model (Fig. 1D). The snf1 mutant exhibits increased
sensitivity to sodium nitrite, decreased melanin production, and
growth on acetate as a sole carbon source at 37°C and is avirulent
inthemurineinhalationmodel(21).Furthermore,arecentstudy
using a serotype D strain of C. neoformans has also shown that
SNF1 deletion impairs growth at 39°C, which is the normal body
temperature for rabbits (28). Therefore, we also tested a major
pathway for 2-carbon utilization via the tricarboxylic acid (TCA)
cycle. ACS1 encodes acetyl-CoA synthase, and the acs1 mutant
fails to grow on 2-carbon substrates and exhibits modestly atten-
uatedvirulenceinthemurine-inhalationalmodelofcryptococco-
sis (21). However, the acs1 mutant showed no defects in CNS
persistence in the rabbit CSF model (Fig. 1D). Taken together,
these data regarding PCK1, SNF1, and ACS1 support the hypoth-
esisthatcarbonassimilationbyC.neoformansfordiseaseproduc-
tion and yeast persistence in the CNS is likely via glycolysis.
Pyruvate kinase is required for C. neoformans pathogenesis
but not persistence in the lung. Since blocked entry of 2- and
3-carboncompoundsintogluconeogenesisbydeletionofACS1or
PCK1showednoadverseeffectonpersistenceofC.neoformansin
the CNS, we sought to deﬁne the speciﬁc role of glycolysis in
persistence of the fungus in the CNS. Therefore, we blocked the
exit of carbon from glycolysis via the deletion of the pyruvate
kinase homolog PYK1. As expected, the pyk1 mutant strain was
unable to grow on glucose, fructose, ribose, or glycerol but was
viable on either acetate or lactate as a sole carbon source (see
Price et al.
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measured by culture absorbance was comparable to that of the
wild type (WT). The pyk1 mutant showed no defects in capsule
or melanin production under inducing conditions and normal
growth at 37°C, and urease activity was similar to that of the WT
(data not shown). Thus, the deletion of PYK1 had no apparent
effects on the classical virulence phenotypes.
Thepyk1mutantdidexhibitseverelydecreasedpersistencein
the rabbit CSF model (Fig. 2A). Its inability to survive in this host
microenvironment was profound. Since the pyk1 mutation re-
stricts carbon utilization to nonpreferred carbon sources like lac-
tate and/or acetate, and since utilization of nonpreferred carbon
sources is restricted in the presence of glucose by CCR, we sought
to alleviate the requirement of using lactate as a sole carbon sub-
stratewhileallowinglactateuseforenergyproductionintheTCA
cycle by impairing CCR. In fungi, two models exist for global
regulation of carbon utilization. For molds such as Aspergillus
nidulans,theMig1ptranscriptionfactorhomologCreAisrespon-
sibleforrepressingtheutilizationofnonpreferredcarbonsources
in the presence of glucose (29). This is different from what was
observedforS.cerevisiae,whereCCRisregulatedbythreediscrete
mechanisms active at different concentrations of glucose (30).
Since CreA is the main repressor in molds and Mig1p-mediated
repressionisactiveatglucoselevelsnearthoseseeninhumanCSF
(30, 31), we deleted a putative MIG1-related carbon catabolite
repressor homolog in both WT and pyk1 backgrounds. The
identity of the MIG1 gene was veriﬁed by real-time PCR (see Ma-
terials and Methods) because we observed repression of the key
gluconeogenesis genes FBP1 and PCK1 in C. neoformans (3- and
169-foldrepressedintheWT,respectively);thesegenesareknown
to be repressed by Mig1p in S. cerevisiae. The resulting pyk1/
mig1 mutant strain should potentially utilize lactate for energy
in the presence of glucose and allow utilization of numerous gly-
colytic metabolites as building blocks for DNA, proteins, etc.
FIG1 PCK1 expression does not correlate with CNS persistence of C. neoformans. (A) PCK1 expression was measured by real-time PCR following exposure to either
CSF or YNB-0.05% glucose (low glucose) for 24 h at 37°C. PCK1 expression following growth in YPD at 37°C (in vitro 37°C) was used as a positive control. (B) PCK1
expressioninC.neoformanswasmeasuredbyreal-timePCRduringrabbitinfection.ExpressionlevelsinvivowerecomparedtothosefromyeastgrowninYPDat37°C
(invitro37°C).(C)PCK1expressionlevelsweremeasuredbyreal-timePCRforC.neoformansisolatedfromhumanCSFsamples.C.neoformansstrains44-1andHC1
were obtained from the Duke University Infectious Disease Specimen Repository, which houses specimens isolated from deidentiﬁed patients with cryptococcal
meningitis. PCK1 transcripts for C. neoformans cultured from the CSF samples and grown in YPD at 37°C (“in vitro” samples) were compared to transcripts isolated
directlyfromtheyeastinCSF(“invivo”samples).(D)LevelsofpersistenceoftheWT,acs1,snf1,orsnf1SNF1mutantstrainsofC.neoformanswerecomparedby
measuringthenumberofCFUofeachstrainisolatedfromtheCSFofmaleNZWrabbitsovertimeasdescribedpreviously(24,42).Rabbitswereinfectedwith108CFU
ofeithertheWT,theacs1,thesnf1,orthesnf1SNF1strain,andfungalburdenwasassessedoverthecourseof2weeksasdescribedinMaterialsandMethods.Missing
data for the snf1 SNF1 strain on day 13 reﬂects the mortality of all these rabbits before day 13. Statistical differences were assessed by an ANOVA comparison of the
graphed lines using the ﬁt model process in JMP version 8 (SAS Institute, Inc., Cary, NC) (*, P0.0001).
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creased persistence in the rabbit CSF model compared to the
pyk1 mutant strain (Fig. 2B), and this was not a CNS-site-
speciﬁc ﬁnding, since both mutants exhibited severely attenuated
virulence in the murine inhalation model (Fig. 2C). To further
deﬁne the mechanism of the attenuated virulence in the murine
inhalation model, fungal viability as measured by tissue colony
countswasobtainedfromlungs,spleen,andbrainofmiceattime
of death (or the end of the experiment for the mutant-infected
mice). As shown in Fig. 2D, despite no apparent evidence of host
disease, substantial numbers of viable cells of both the pyk1 and
pyk1/mig1 mutants were recovered from mouse organs after
42 days postinfection. Additionally, colony counts were lower for
thepyk1/mig1mutantstrainthanforthepyk1strain.Clearly,
these mutants can survive for long periods of time in the murine
host without producing disease yet are unable to do so in the
rabbitCSFmodelwheretheydonotproducediseaseandareelim-
inated from the site of infection.
HexosekinaseactivityisimportantforC.neoformanspatho-
genesis. To more directly assess the mechanistic effect of glucose
utilization on virulence of C. neoformans in the host, we blocked
glycolysis at the entry point of glucose into the glycolysis pathway
via the concurrent deletion of the putative hexose kinase ho-
mologs HXK1 and HXK2. Unlike the model yeast S. cerevisiae,
which has three hexose kinase genes, C. neoformans possesses two
putative hexose kinase genes, as observed in A. nidulans (22, 32).
WhereasthesinglehexosekinasemutantsandtheWTstrainwere
fully virulent, concurrent deletion of both putative hexose kinase
genesbythecreationofadoubleknockoutmutationinC.neofor-
mans signiﬁcantly decreased fungal persistence in the rabbit CSF
model (Fig. 3A). The hxk1/hxk2 mutant also showed pro-
foundly attenuated virulence in the murine inhalation model of
cryptococcosis,comparedtothesinglemutantsandtheWTstrain
(Fig. 3B), without apparent defects in capsule production (data
notshown).Surprisingly,subsequentanalysisofthefungalcensus
from various mouse organs obtained from the murine inhalation
study revealed that both the single and the double mutant strains
wererecoveredfrommiceatthetimeofdeathinsimilarnumbers,
yet the speeds of disease progression were dramatically different
(i.e., at the end of the experiment [21 days postinfection for the
FIG2 Uncouplingofglycolysisfromoxidativephosphorylationresultsincompleteattenuationofvirulence,butnotpersistence,ofC.neoformans.NZWrabbits
were infected with either the WT, pyk1,o rpyk1 PYK1 strain (A) or the WT, mig1, pyk1,o rpyk1/mig1 strain (B) of C. neoformans as described in
Materials and Methods. Differences between strains were assessed by an ANOVA using the ﬁt model process in JMP version 8 (SAS Institute, Cary, NC) (*, P 
0.0001).Missingdataformig1day10reﬂectsthemortalityofalltheserabbitsbeforeday10.(C)A/JcrinbredmicewereinfectedpernasallywiththeWT,pyk1,
pyk1 PYK1,o rpyk1/mig1 strain of C. neoformans. The mice were observed over the course of the experiment for clinical signs correlating with eventual
mortality (*, P  0.0001; log rank test). (D) Fungal burden was assessed for three mice per group from the virulence study described for panel C. Organs were
removed at time of death (~21 days postinfection for the WT and pyk1 PYK1 strains; 42 days postinfection for the pyk1 and pyk1/mig1 strains) and
processed for fungal burden as described elsewhere (70). Differences in numbers of CFU between each mutant strain and the WT for each organ were assessed
using Student’s t test (*, P  0.01). Missing data for pyk1 mig1 spleen counts reﬂect an absence of CFU detected in this sample.
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hxk1/hxk2 mutant]) (Fig. 3C).
Given the results of the pyk1, pyk1/mig1, and hxk1/hxk2
mutants in both animal models, we elected to study the long-term
effects of these mutations on yeast survival in the murine inhalation
model.MicewereinfectedwitheithertheWT,thepyk1,thepyk1/
mig1,o rt h ehxk1/hxk2 strain and evaluated every 3 weeks for
fungal burden in both brain and lung tissues. These mutants did not
successfullyestablishapersistentinfectioninthebrainsofthesemice
during the duration of the study (data not shown). However, all 3
mutantssuccessfullycolonizedthelungs(Fig.4A),andevaluationof
these mice for signs of morbidity revealed differences in virulence in
this model not previously observed (Fig. 4B). Surprisingly, the
hxk1/hxk2mutantwasshowntobevirulentandcausedmortality
in these mice after 6 weeks postinfection. The pyk1 mutant also dis-
played some virulence capacity, although by 21 weeks postinfection,
thisstrainwasclearedbythemice.Interestingly,impairmentofCCR
in the pyk1background via the concurrent deletion of MIG1 com-
pletelyabolishedmortalitycomparedtothelevelforthepyk1single
mutant and conferred prolonged persistence of the yeast in the lung
(Fig. 4). Despite their common effects on glucose assimilation via
glycolysis, either at the point of entry of glucose into glycolysis
(hxk1/hxk2) or directly before entry of pyruvate into the TCA
cycle (pyk1), virulence is severely affected, yet the ﬁnal dispositions
of these glycolysis mutants within the host are clearly different.
C. neoformans glycolysis mutants exhibit different host
stresssusceptibilitiesduringinfection.Tounderstandthemech-
anism(s) surrounding the impact of glycolytic interruptions on
host outcomes, and since glycolysis provides metabolites for en-
ergy production via oxidative phosphorylation, we quantiﬁed
ATP production in the pyk1 mutants following exposure to hu-
man CSF in vitro to determine a possible link between energy
production and virulence in the subarachnoid space. Following
1 h of CSF exposure, the pyk1 mutant possessed equal amounts
of ATP per g protein compared to the WT (Fig. 5A). However,
after 24 h of CSF exposure, the pyk1 mutant exhibited signiﬁ-
cantly less ATP than the WT. Removing carbon catabolite repres-
sion in the pyk1 background (i.e., pyk1/mig1) did not com-
pletely alleviate this energy production deﬁciency in ex vivo
human CSF (Fig. 5A). To further differentiate whether this deﬁ-
FIG 3 Glucose utilization via hexose kinase is required for virulence but not persistence of C. neoformans. (A) NZW rabbits were infected with either the WT,
the hxk1, the hxk2,o rt h ehxk1/hxk2 strain of C. neoformans as described in Materials and Methods. Differences between strains were assessed by an
ANOVAusingtheﬁtmodelprocessinJMPversion8(SASInstitute,Inc.,Cary,NC)(*,P0.001).Missingdataforthehxk1andhxk2strainsforday10reﬂect
the mortality of all these rabbits before day 10. (B) A/Jcr inbred mice were infected per nasally with the WT, hxk1, hxk2,o rhxk1/hxk2 strain of
C.neoformans.Themicewereobservedoverthecourseoftheexperimentforclinicalsignscorrelatingwitheventualmortality(*,P0.0002;logranktest).(C)
Fungal burden was assessed for three mice per group from the virulence study described for panel B. Organs were removed at the time of death (~21 days
postinfection for the WT, hxk1, and hxk2 strains; 42 days postinfection for the hxk1/hxk2 strain) and processed for fungal burden as described elsewhere
(70). Differences in numbers of CFU between each mutant strain and the WT for each organ were assessed using Student’s t test (*, P  0.01).
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more generally to the blocked entry of numerous carbon metab-
olitesintooxidativephosphorylation,wealsoexaminedATPpro-
ductioninthehexosekinasemutants(Fig.5B).Thehxk1/hxk2
mutant is completely unable to grow on glucose as a sole carbon
source but can utilize other carbon sources, such as glycerol or
lactate(seeFig.S2inthesupplementalmaterial).Interestingly,no
statistically signiﬁcant differences were observed between the
hexose kinase single or double mutants and the WT, supporting
theconclusionthattheATPproductiondefectinCSFisduetothe
impairedabilityofthepyk1mutantstomovecarbonmetabolites
into the TCA cycle as substrates for oxidative phosphorylation.
To determine the cause of the attenuation in virulence in the
hxk1/hxk2 mutant if energy production is not an issue, we
performed a macrophage-killing assay. This assay allowed us to
assess the ability of strains to survive and proliferate in an intra-
cellular environment. As shown in Fig. S3 in the supplemental
material, defects at the beginning and end of glycolysis result in
reduced survival within host cells. In fact, the hxk1/hxk2 mu-
tant is particularly susceptible to killing by macrophages, as this
mutant was signiﬁcantly reduced in survival compared to all other
mutant strains tested in this macrophage assay. The hxk1/hxk2
mutant result is at least somewhat explained due to this mutant’s
increasedsusceptibilitytohydrogenperoxideandnitricoxidekilling
compared to that of the other mutant strains that show no added
sensitivity compared to the WT (H2O2 MIC  250 M for the
hxk1/hxk2 mutant versus 2,000 M for the WT; NO MIC 
62.5 M for the hxk1/hxk2mutant versus 250 M for the WT).
DISCUSSION
Previous studies by others investigating various carbon metabolic
pathways in fungal pathogens have shown the importance that
FIG 4 Pyruvate kinase mutants exhibit enhanced persistence in the lung
without disease production. A/Jcr inbred mice were infected per nasally with
the WT, pyk1, pyk1/mig1,o rhxk1/hxk2 strain of C. neoformans in
order to assess the persistence of these strains in vivo. (A) Fungal burden in
lung tissues was assessed for three mice per strain every 3 weeks following
infectionasdescribedelsewhere(70).Braintissuesfromthesemiceshowedno
fungal burden over the course of the experiment. (B) The mice in the fungal
burden assay were also observed over the course of the experiment for clinical
signs correlating with eventual mortality (15% loss of body weight, lack of
grooming, etc.). The survival of mice not sampled at the predetermined end-
points was assessed for similarity to the WT level. All mutant strains showed
statistically signiﬁcant differences from the WT (P  0.0001; log rank test).
FIG 5 Mutations blocking glucose utilization produce varied effects on ATP
production in ex vivo human CSF. WT and mutant strains of C. neoformans
were grown in YPL shake culture at 37°C to saturation, then centrifuged,
washed with sterile PBS, and resuspended in ﬁlter-sterilized pooled human
CSF. These CSF shake cultures were then incubated at 37°C, with 15-ml ali-
quotsremovedat1hand24h,andprocessedasdescribedelsewhere(67).(A)
MeasurementofATPlevelsintheWT,pyk1,pyk1PYK1,pyk1/mig1,and
mig1 strains following exposure to ex vivo C S Ff o r1ho r2 4h .Differences
between mutant strains and the WT at each time point were compared using
Student’s t test (*, P  0.005). (B) Measurement of ATP levels in the WT,
hxk1,hxk2,andhxk1/hxk2strainsfollowingexposuretoexvivoCSFfor
1hor24h.DifferencesbetweenmutantstrainsandtheWTateachtimepoint
were compared using Student’s t test (  0.05).
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rate lyase is a gateway enzyme for the glyoxylate shunt that allows
for the utilization of 2-carbon compounds such as acetate and
ethanol (18, 33, 34). The glyoxylate shunt has been shown to play
a signiﬁcant role in the virulence of numerous plant and animal
pathogenic fungal species and interacts with the -oxidation
pathway for fatty acid utilization, as isocitrate lyase mutants in
other fungal systems are also unable to utilize fatty acids as sole
carbonsources(18,35–38).However,thesedatafromotherfungi
standindirectcontrasttoobservationsinC.neoformansandA.fu-
migatus, where carbon acquisition via the glyoxylate shunt is not
required for virulence (22, 24, 39, 40).
Inthecurrentstudy,wehavefurtherdeﬁnedthecarbonassim-
ilationpathwaysinC.neoformansnecessaryforgrowthindiscrete
hostmicroenvironments.Weemployedtwodifferentyetcomple-
mentary models of C. neoformans virulence, the murine inhala-
tion model and the rabbit CSF model (41, 42). The murine inha-
lation model corresponds closely to the mechanism of human
infection, whereas the rabbit CSF model allows us to speciﬁcally
probe the inﬂuence of the various carbon utilization pathways on
CNS persistence. The linkage of gluconeogenesis via Pck1 (see
Fig. S1 in the supplemental material) to C. neoformans virulence
was ﬁrst made using a random-insertion mutagenesis screen that
identiﬁed the virulence-associated DEAD box RNA helicase gene
VAD1 by the Williamson laboratory (23). PCK1 is regulated in
part by Vad1, encodes a key enzyme for entry of 2- and 3-carbon
compounds into gluconeogenesis, and is upregulated in response
to low glucose levels. The pck1 deletion strain of C. neoformans
exhibits severely attenuated virulence in a murine inhalation
model of cryptococcosis (23). Using a separately constructed
pck1 strain, we have shown that although the gene is highly up-
regulatedinthelow-glucoseenvironmentoftheCSF,lossofPCK1
yields no impact on persistence of Cryptococcus in the rabbit CSF
model of cryptococcosis (Fig. 1).
Likewise, a prior study demonstrated roles for the nonpre-
ferred carbon utilization regulatory kinase gene SNF1 and the
acetyl-CoA synthase gene ACS1 in C. neoformans virulence in a
murine inhalation model (21). Interestingly, these mutations ei-
thermoderatelyaffectedorhadnoeffectonpersistenceofC.neo-
formansintherabbitCSFmodelofdisease,whichplacesdifferent
host site demands on the yeast regarding establishment of infec-
tion compared to those in the murine inhalation model (Fig. 1).
These gluconeogenesis-related gene data, along with previously
published data on ICL1 (24) and MLS1 (22), which demonstrate
no defects in virulence due to lost glyoxylate-shunt function,
clearly show that gluconeogenesis is not primarily utilized by
C. neoformans to procure nonpreferred carbon (e.g., lactate, ace-
tate, etc.) during growth in the CNS.
The obvious alternative to using gluconeogenesis for carbon
acquisitionintheCNSisglycolysis.Previousstudiesofcryptococ-
cosis have touched on pathways linked to glycolysis but have not
explicitly addressed the glycolysis pathway and its linkage to the
virulence composite of C. neoformans. For example, the trehalose
biosynthesispathwayhasbeenstudiedforbothC.neoformansand
C. gattii (43, 44). In the most recent study, the relationship be-
tween trehalose biosynthesis and hexose kinase activity was dem-
onstrated via the ability of individual hexose kinase deletion mu-
tants to suppress the temperature-sensitive (ts) phenotype of the
trehalose pathway mutants (43). However, the speciﬁc effect of
hexose kinase deletions on the virulence composite was not ad-
dressed. Therefore, in this study we showed that hexose kinase
activity for glucose utilization is critical both for virulence in the
murine inhalation model of cryptococcosis and for acute persis-
tence in the rabbit CSF model (Fig. 3 and 4).
Thedeﬁnedrolesofhexosekinaseinglucosecataboliterepres-
sion and glucose metabolism (reviewed in reference 45) allowed
ustobegintoteaseapartglucoseutilizationversusenergyproduc-
tioninregardtotheireffectonvirulenceandgrowthofC.neofor-
mans in the host. Three different mechanisms for glucose catabo-
lite repression that are dependent on the level of extracellular
glucose have been described for S. cerevisiae: the Mig1p-
independent pathway (very low glucose), the Ras/cyclic AMP
(cAMP) pathway (low glucose), and the Mig1p-dependent path-
way(highglucose)(30).IntheMig1p-mediatedglucosecatabolite
repression pathway, Hxk2p interacts with Mig1p to enter the nu-
cleus and bind as a complex to glucose-repressible genes (re-
viewedinreference45).Ourdatashowaprofoundattenuationof
virulence due to blocked metabolism of glucose in the hxk1/
hxk2doublemutant,inspiteofadequatepersistenceofthismu-
tant strain in the host (Fig. 3B and C and 4). However, ATP pro-
duction in ex vivo CSF was unaffected by deletion of both hexose
kinases(Fig.5B).Therefore,thesedatasuggestthatintheabsence
of normal Hxk2/Mig1-mediated glucose repression (due to a lack
ofHxk2),nonpreferredcarbonsourcesareabletoadequatelysus-
tain survival of the yeast in the host, with delayed expression of
disease symptoms.
We have also demonstrated the importance of glucose metab-
olism to virulence by examining the role of pyruvate kinase, lo-
cated at the opposite end of the glycolytic pathway from hexose
kinase (see Fig. S1 in the supplemental material). In these studies,
blockingglycolysisviadeletionofPYK1againresultsinattenuated
virulence,albeitapparentlyforadifferentreason.ATPproduction
in the pyk1 mutant was severely impaired after only 24 h of
exposuretoexvivoCSF(Fig.5A);thisdemonstratesamechanism
for the adverse effect on persistence in the host CSF through re-
duction in energy formation (Fig. 2A and D). However, glucose
catabolite repression is still active in the pyk1 mutant, and even
though ample lactate is present in CSF, it may not be available for
use. Therefore, we attempted to alleviate Mig1-mediated glucose
catabolite repression through the deletion of the candidate MIG1
gene in the pyk1 background and were able to partially restore
ATP production (Fig. 5A). Interestingly, persistence in the host
CSF was made even worse than that obtained with the single
pyk1mutant(Fig.2BandD).Inotherfungalsystems,deletionof
MIG1 (or its homolog creA) results in reduced/altered growth
(46–48).ItispossiblethatlossofMig1-mediatedrepressioninthe
pyk1/mig1 mutant further impairs growth by allowing many
carbon metabolic pathways to be activated due to the availability
ofallpresentcarbonsourcesinthehost.Theputativeactivationof
these metabolic pathways may simply outstrip the ability of avail-
able lactate to provide adequate ATP via oxidative phosphoryla-
tion, due to the block at the step of Pyk1. Alternatively, loss of
Mig1-mediated repression may lead to increased activity of alter-
nate glucose repression pathways, as has been described for dele-
tionofHXK2inbuddingyeast(49),orotherpleiotropiceffects,as
has been demonstrated for SNF1. Additional experiments will
need to be performed to address this issue.
Taken together, the hxk1/hxk2 and pyk1 data support the
hypothesis that blocks at different steps in glycolysis can result in
completely different mechanisms for virulence attenuation. The
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ATP(Fig.5B),butitshowsincreasedsensitivitytoreactiveoxygen
species (ROS) and reduced intracellular growth likely due to
blocked movement of glucose-6-phosphate into the pentose
phosphate pathway (50, 51). The hexose kinase and pyk1 single
mutantsalsoexhibiteddecreasedsurvivalinthemacrophageassay
but did not demonstrate particular sensitivity to ROS or nitric
oxide, suggesting that the decreased survival in macrophages may
have been more closely related to the use of glucose in the media
necessitatedbythisassay.Still,thehxk1/hxk2mutantdidshow
signiﬁcantly decreased survival in macrophages compared to the
correspondingsinglemutantsanddisplaysincreasedsensitivityto
ROScomparedtoallotherstrainsinthisstudy,suggestingthatthe
hxk1/hxk2 mutant phenotype in vivo may be at least partially
due to decreased survival in macrophages. Interestingly, this in-
creasedROSsensitivityshouldslowtheproliferationoftheorgan-
ism in the host, yet our data show that it mayeventually adapt and
kill the host (Fig. 3C and 4B). Alternatively, blocking efﬁcient ATP
(energy) production by deletion of PYK1 (Fig. 5A) produces a strain
thatdoesnotcompletelydieinthehostbutpersistsforlongperiodsof
time(Fig.4).IntherabbitCSFmodelofacuteinfection,bothblocks
inglycolysisprovidesubstantialchallengesforthesurvivaloftheyeast
inthisbiologicalﬂuidandtheCNSsiteofinfection(Fig.2Aand3A).
Mechanistically, it has previously been shown that activated
macrophages inhibit growth of C. neoformans in vitro (52). The
speciﬁcmechanismofgrowthinhibitionbymacrophageswasﬁrst
describedinregardtointeractionswithneoplastictumorcellsand
involved the inhibition of mitochondrial oxidative phosphoryla-
tionintheneoplasticcells(53,54),whichisphenotypicallysimilar
to the effect observed in C. neoformans, another eukaryote. It is
possible that this yeast interaction with activated macrophages in
immunocompetent hosts results in dormancy of the fungus
through reduction or elimination of its energy production, which
is then able to reestablish infection later when host immune con-
ditions are reduced and thus more conducive for yeast growth by
eliminating the block in energy production (55). The pyk1 muta-
tion actually mimics impaired oxidative phosphorylation, as evi-
dencedbythedecreaseinATPproductionobservedinCSF(Fig.5A),
and further shows greatly impaired proliferation in association with
anactivatedmacrophage-likecellline(seeFig.S3inthesupplemental
material). These data, along with the long-term persistence data
(Fig. 4), allude to the establishment of a dormant-like state in the
pyk1 mutants due to disrupted oxidative phosphorylation since
these cells are viable without causing disease. Therefore, we believe
thatthepyk1mutantsmayserveasgoodmodelstrainsforstudying
the proposed yeast energy impact on dormancy of C. neoformans.
TheimpactofATPproductiononpersistencehasimplicationsfor
future antifungal development. For example, the importance of glu-
cose metabolism on cancer growth is the subject of considerable re-
searchandisfairlywellunderstood(25).Indeed,glycolysisinhibitors
arecurrentlyinvariousstagesofclinicaltrialsasviabletreatmentsfor
cancer(26)andmaybeofadditionalbeneﬁtininstanceswhereanti-
cancerdrugresistanceisanissue(56).Therefore,glycolysisinhibitors
mayprovidesimilarbeneﬁtsintheprophylaxisandtreatmentoffun-
gal diseases such as cryptococcosis. The ﬁndings presented in this
work suggest new targets for antifungal therapy that may help allevi-
ate the problem of antifungal drug resistance by attacking slow-
growing or dormant yeast cells.
MATERIALS AND METHODS
Strainsandmedia.TheCryptococcusneoformansstrainsusedinthisstudy
are listed in Table S1 in the supplemental material. The C. neoformans
44-1 and HC1 strains are clinical isolates from deidentiﬁed patients with
cryptococcal meningitis and were procured from the Duke University
Infectious Disease Specimen Repository. All gene deletions were per-
formed in the C. neoformans H99 strain background. Strains were grown
using standard yeast media as described previously (57). The 20% lactate
solutionusedtoprovideacarbonsourceforthepyk1mutantstrainswas
preparedbydilutingconcentrated D,L-lacticacid(itemno.L6661;Sigma-
Aldrich, St. Louis, MO) in sterile distilled H2O (dH2O) and adjusting the
pH of the solution to ~4.5 by adding 5.8 g/liter NaOH. Selective media
contained either nourseothricin (clonNAT; 100 mg/liter; Werner BioAg-
ents, Jena-Cospeda, Germany) or geneticin (G418; 200 mg/liter; Invitro-
gen Corp., Carlsbad, CA) for selection of transformants. Capsule-
inducing medium (Dulbecco’s modiﬁed Eagle’s medium [DMEM] with
orwithout22mMNaHCO3buffer,10%NCTC109,10%fetalcalfserum,
1% minimal essential medium [MEM] nonessential amino acid solution,
1% penicillin-streptomycin) was prepared as previously described (58),
using carbon sources conducive for growth of the various mutant strains.
Melaninproductionwasvisuallyassessedusingdopamineagar(59).Ure-
ase activity was veriﬁed as previously described (60).
Gene deletions. We identiﬁed the C. neoformans PCK1 (CNAG_04217),
PYK1 (CNAG_01820), HXK1 (CNAG_05480), and MIG1 (CNAG_06327)
genes by searching the C. neoformans H99 predicted-protein database avail-
able from the Broad Institute (http://www.broadinstitute.org/annotation
/genome/cryptococcus_neoformans/MultiHome.html), using a BLASTp
homology search with the Pck1p, Pyk1p, Hxk1p, and Mig1p protein se-
quencesfromS.cerevisiae.GenescarryingHXK2(CNAG_03769),ACS1,and
SNF1havepreviouslybeenidentiﬁedandarelistedinTableS1inthesupple-
mental material. The PCK1 and PYK1 gene homologs are present in the
C. neoformans genome as single copies, with 66% and 64% identity to the
correspondingS.cerevisiaeproteinsequences,respectively.Hxk1shows35%
identity to S. cerevisiae Hxk1p and has previously been identiﬁed (22). C.
neoformans Mig1 exhibits 80% and 89% identity to the S. cerevisiae Mig1p
and A. nidulans CreA putative DNA binding domains, respectively.
After identifying the loci of these genes in the H99 genome, we con-
structed PCR primers to delete the genes using established methods (see
Table S2 in the supplemental material) (61). Gene deletions were veriﬁed
by Southern hybridization (62), and previously unpublished gene dele-
tion strains with altered phenotypes were complemented by reintroduc-
tionofthenativegenebybiolistictransformationaspreviouslydescribed
(63). A functional role for the MIG1 gene in the regulation of gluconeo-
genesis was established by comparison of transcription of putative Mig1-
regulated genes (ACS1, PCK1, and FBP1) between the WT and mig1
strains as described below for real-time PCR.
Carbon utilization screen. The WT, pyk1, pyk1 PYK1, pyk1/
mig1, mig1, pck1, hxk1, hxk2, and hxk1/hxk2 strains were
grown to saturation in 5 ml of either yeast extract-peptone-dextrose
(YPD)oryeastextract-peptone-lactate-rafﬁnose(YPLR;1%yeastextract,
2% peptone, 2% lactic acid, 1% rafﬁnose) broth, counted using a hemo-
cytometer, and diluted to 2  107 CFU/ml in sterile phosphate-buffered
saline (PBS). A 10-fold dilution series from 2  107 to 2  104 CFU/ml
wasmadeforeachstrain,and5lofeachdilutionwasspottedontoyeast
nitrogenbase(YNB)-2%glucose,YNB-3%glycerol,andYNB-2%lactate.
The plates were incubated at 30°C for 2 to 4 days and photographed.
RNA preparation. Total RNA was extracted from lyophilized cells
usingTRIzolreagent(InvitrogenCorp.,Carlsbad,CA)andpuriﬁedusing
a Qiagen RNeasy kit (Qiagen, Inc., Valencia, CA) in accordance with the
manufacturer’sinstructions.RNAsampleswerethenstoredat80°Cfor
later analysis. For the evaluation of PCK1 expression from anonymous
human samples, RNA was extracted from either fresh (in vivo) or subcul-
tured (in vitro) harvested cells.
Real-time PCR. cDNA was prepared from RNA puriﬁed as described
above, using a RETROscript kit (Applied Biosystems/Ambion, Austin,
Price et al.
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described (64), using primers listed in Table S1 in the supplemental ma-
terial. Transcript ampliﬁcation for PCK1 from each strain and condition
wasnormalizedtotheampliﬁcationoftheconstitutivelyexpressedGPD1
gene(65).FortheexvivoCSFandinvivorabbitexpressionassays,changes
in transcript levels were calculated relative to the expression of PCK1 in
the WT grown in YPD at 37°C in shake culture.
To verify the identity of the MIG1 gene, the WT and mig1 strains
were grown in 50 ml YPD shake culture at 30°C overnight, washed once
withsteriledH2O,andresuspendedinfreshYPDthefollowingdayfor1h
at 30°C. Following this incubation, the cultures were centrifuged, and the
cellpelletswerefrozenat80°CforRNApreparationasdescribedabove.
ThetranscriptionlevelsofACS1,FBP1,andPCK1werenormalizedtothe
level for the constitutively expressed GPD1 gene in both strains. Differ-
ences in expression (n-fold) were calculated using the Bio-Rad iCycler
software system, which utilizes the comparative cycle threshold statistical
methods as previously described (66).
Measurement of ATP levels. Cellular ATP levels were measured as
previously described (67), following in vitro CSF exposure. Brieﬂy, fresh
colonies of the WT, pyk1, pyk1 PYK1, pyk1/mig1, mig1, hxk1,
hxk2, and hxk1/hxk2 strains were grown in 30 ml of YPL broth to
saturation at 37°C with shaking. The cultures were centrifuged at
3,000 rpm for 5 min, washed once with PBS, resuspended in 30 ml of
ﬁlter-sterilizedpooledhumanCSF,andincubatedat37°Cwithshaking.A
15-ml aliquot of each culture was removed after 1 h and 24 h and pro-
cessed as follows: 10 ml was centrifuged and washed once with PBS, and
thepelletwasstoredat80°C;5mlwascentrifugedandwashedoncewith
PBS,andthepelletwasstoredovernightat80°Cinscrew-cap2-mltubes
foranalysisintheATPassay.PelletsforATPanalysiswereresuspendedin
1mlof50mMHEPES(pH7.7)anddisruptedusingaMiniBeadBeater-16
(BioSpec Products, Inc., Bartlesville, OK) with 6.3-mm stainless steel
beads.Samplesweredisruptedusingone45-spulseandkeptonicebefore
and after disruption. The disrupted samples were centrifuged at
5,000 rpm at 4°C for 10 min, and the supernatants were collected to
determine ATP concentrations using an ATP bioluminescence assay kit
(Sigma-Aldrich, St. Louis, MO). Soluble-protein concentrations were
measured for an aliquot of the supernatant from each sample using the
Bradfordassay(68).ATPconcentrationswerenormalizedfordirectcom-
parison using soluble-protein concentrations for each sample. The mean
measurements for three separate experiments are reported.
In vivo virulence experiments. Virulence of the C. neoformans strains
wasassessedusingbothamurineinhalationmodelandarabbitCSFmodelof
cryptococcosis as previously described (42, 69). For the murine inhalation
model, female A/Jcr mice were intranasally inoculated with 105 CFU/ml of
eachC.neoformansstrain(10miceperstraininsurvivalstudies;3miceforthe
WT and 27 mice per mutant strain for the fungal persistence study). For the
rabbitCSFmodel,maleNewZealandWhite(NZW)rabbitsweretreatedwith
cortisone via daily injection and intrathecal inoculation into the subarach-
noid space with 108 CFU of each C. neoformans strain (3 rabbits per group).
Animals were evaluated daily for signs of morbidity and were sacriﬁced at
predetermined clinical endpoints correlating with mortality per approval
from the Duke Institutional Animal Care and Use Committee Guidelines.
Differences between strains in the murine inhalation model were assessed
using the log rank test in JMP version 8 (SAS Institute, Inc., Cary, NC). Dif-
ferences between strains in the rabbit CSF model were determined by an
analysis-of-variance (ANOVA) comparison using the Fit Model process in
JMP version 8.
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